| 200 |
| $4K |
| — |
| 0.000% |
| 0.00% |
| 4 | EverSource Wealth Advisors, LLC | 24 | $421 | 0.0% | 0.000% | 0.00% |
| 5 | UBS Group AG | 15 | $263 | -87.9% | 0.000% | 0.00% |
| 6 | BlackRock, Inc. | 6 | $105 | — | 0.000% | 0.00% |
| 7 | Caitong International Asset Management Co., Ltd | 1 | $18 | — | 0.000% | 0.00% |
| 8 | ROYAL BANK OF CANADA | 6 | $0 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in AAPG — a direct measure of their conviction.
| 0.25% |
| — |
| $5M |
| — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
3 institutions opened new positions in AAPG during Q2 2026, while 2 fully exited. 1 added to existing positions and 3 trimmed.
AAPG institutional ownership fell by 0.01 percentage points quarter-over-quarter, with a net change of +1 holders.
The top 10 institutions account for 100.0% of all reported 13F value in AAPG, and the top 25 account for 100.0%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.